Molecular Partners Competitors and Similar CompaniesClear all
Molecular Partners's competitors and similar companies include Brii Biosciences, Design Therapeutics, Thor Medical and Abliva.
 Molecular Partners Molecular Partners is a company that develops biopharmaceutical products for serious diseases. |  Brii Biosciences Brii Biosciences researches and develops medicines for the treatment of chronic illnesses with significant burdens, including infectious diseases, liver and lung diseases, and other illnesses. |  Design Therapeutics Design Therapeutics is a biopharmaceutical company engaged the research and development of small-molecule gene targeted chimera therapeutic candidates. |  Thor Medical Thor Medical (formerly known as Nordic Nanovector) is a biopharmaceutical company that focuses on the development and commercialisation of novel targeted therapeutics in haematology and oncology. |  Abliva Abliva is a biotech company that discovers and develops medicines for the treatment of mitochondrial disease. | |
Founding Date | Founding Date 2004 | Founding Date 2018 | Founding Date 2017 | Founding Date 2009 | Founding Date 2000 |
Type | Type Public | Type Private | Type Public | Type Public | Type Subsidiary |
Tags | |||||
Locations | Locations Zürich-Schlieren, CH HQ Cambridge, US Concord, US | Locations CN HQ Beijing, CN Durham, US San Francisco, US San Mateo, US | Locations Carlsbad, US HQ | Locations Oslo, NO HQ Zug, CH Shrewsbury, GB | Locations Lund, SE HQ |
Employees | Employees 158 | Employees 8510% decrease | Employees 54 | Employees 3716% decrease | Employees 950% increase |
Valuation ($) | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 313.1 m | Valuation ($) 131.4 m | Valuation ($) N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) kr439k (FY, 2025) | Revenue (est.) N/A |
Cost of goods | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit N/A | Gross profit N/A | Gross profit N/A | Gross profit kr4.3m (FY, 2025) | Gross profit kr497k (FY, 2024) |
Net income | Net income (CHF61.7m) (FY, 2025) | Net income N/A | Net income ($69.8m) (FY, 2025) | Net income (kr58m) (FY, 2025) | Net income (kr90m) (FY, 2024) |
Funding | |||||
Total funding raised | Total funding raised N/A | Total funding raised $ 415m | Total funding raised $ 45m | Total funding raised N/A | Total funding raised $ 10.8m |
For sources of this data, please see the company profile
View Company Profiles
Brii Biosciences
HQ
CN
Employees
85↓ 10% decrease
Brii Biosciences researches and develops medicines for the treatment of chronic illnesses with significant burdens, including infectious diseases, liver and lung diseases, and other illnesses.
View companyDesign Therapeutics
HQ
Carlsbad, US
Employees
54
Design Therapeutics is a biopharmaceutical company engaged the research and development of small-molecule gene targeted chimera therapeutic candidates.
View companyThor Medical
HQ
Oslo, NO
Employees
37↓ 16% decrease
Thor Medical (formerly known as Nordic Nanovector) is a biopharmaceutical company that focuses on the development and commercialisation of novel targeted therapeutics in haematology and oncology.
View companyAbliva
HQ
Lund, SE
Abliva is a biotech company that discovers and develops medicines for the treatment of mitochondrial disease.
View company